The objective of the Oligopeptide Facility is to provide primary structural data on various proteins and peptides under study by members of the Cancer Center and other faculty of the University of Chicago and outside. Services that are provided by the facility include amino acid analysis or composition of proteins, amino-terminal amino acid sequence analysis of proteins/peptides, and the production of synthetic peptides. In addition, the facility provides individualized consultation to Cancer Center researchers to enable them to design, synthesize, sequence and analyze peptides, and workshops for all interested staff and faculty. The peptide microsequencing capability of this Core provides CRC investigators with amino acid sequence data from extremely small quantities of protein for the purposes of identification of the protein product where the sequence is known, comparison with protein sequence information for determination of similarity and generating synthetic peptides for further biological and molecular characterization of these proteins. The peptide synthetic capability of the core provides CRC investigators with the ability to investigate peptides of interest to them through generation of antibodies, isotope mapping or assessment of biological properties. This facility was opened in March, 1988. Thirty-four Cancer Center investigators are users of the facility. The apparent need is mostly for peptides to produce antibodies or epitope mapping. The Core attempts to remain responsive to the needs of the Cancer Center members, determines priority of services, and keeps Center members informed of new developments and technical advances.

Agency
National Institute of Health (NIH)
Institute
National Cancer Institute (NCI)
Type
Center Core Grants (P30)
Project #
5P30CA014599-27
Application #
6397831
Study Section
Project Start
2000-08-01
Project End
2002-03-31
Budget Start
1998-10-01
Budget End
1999-09-30
Support Year
27
Fiscal Year
2000
Total Cost
$289,716
Indirect Cost
Name
University of Chicago
Department
Type
DUNS #
225410919
City
Chicago
State
IL
Country
United States
Zip Code
60637
Kathayat, Rahul S; Cao, Yang; Elvira, Pablo D et al. (2018) Active and dynamic mitochondrial S-depalmitoylation revealed by targeted fluorescent probes. Nat Commun 9:334
Liu, Jun; Eckert, Mark A; Harada, Bryan T et al. (2018) m6A mRNA methylation regulates AKT activity to promote the proliferation and tumorigenicity of endometrial cancer. Nat Cell Biol 20:1074-1083
Bhanvadia, Raj R; VanOpstall, Calvin; Brechka, Hannah et al. (2018) MEIS1 and MEIS2 Expression and Prostate Cancer Progression: A Role For HOXB13 Binding Partners in Metastatic Disease. Clin Cancer Res 24:3668-3680
Wood, Kevin; Byron, Elizabeth; Janisch, Linda et al. (2018) Capecitabine and Celecoxib as a Promising Therapy for Thymic Neoplasms. Am J Clin Oncol 41:963-966
Sample, Ashley; Zhao, Baozhong; Wu, Chunli et al. (2018) The Autophagy Receptor Adaptor p62 is Up-regulated by UVA Radiation in Melanocytes and in Melanoma Cells. Photochem Photobiol 94:432-437
Hrusch, C L; Manns, S T; Bryazka, D et al. (2018) ICOS protects against mortality from acute lung injury through activation of IL-5+ ILC2s. Mucosal Immunol 11:61-70
Hope, C Matthew; Webber, Jemma L; Tokamov, Sherzod A et al. (2018) Tuned polymerization of the transcription factor Yan limits off-DNA sequestration to confer context-specific repression. Elife 7:
Wu, Chengyue; Pineda, Federico; Hormuth 2nd, David A et al. (2018) Quantitative analysis of vascular properties derived from ultrafast DCE-MRI to discriminate malignant and benign breast tumors. Magn Reson Med :
Wong, Gabrielle S; Zhou, Jin; Liu, Jie Bin et al. (2018) Targeting wild-type KRAS-amplified gastroesophageal cancer through combined MEK and SHP2 inhibition. Nat Med 24:968-977
Ni, Kaiyuan; Lan, Guangxu; Chan, Christina et al. (2018) Nanoscale metal-organic frameworks enhance radiotherapy to potentiate checkpoint blockade immunotherapy. Nat Commun 9:2351

Showing the most recent 10 out of 668 publications